Benzinga · Oct 1, 2026
Guggenheim Maintains Buy on Bruker, Raises Price Target to $72
Guggenheim analyst Subbu Nambi maintains Bruker (NASDAQ:BRKR) with a Buy and raises the price target from $70 to $72.
NYSE · BRKR
Bruker Corporation
Healthcare · Medical - Devices
$58.84
Up+$0.92 (+1.59%)
Updated Oct 10, 2026, 11:42 PM
SID Score
6.5/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 7.04B
- P/E ratio
- -355.31
- Dividend yield
- 0.34%
- 52-week range
- $32.37 – $66.98
- Volume
- 1.47M
- Avg. volume
- 3.15M
Price performance · BRKR
BRKR price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
BRKR closed at $58.84 after 21 trading sessions, up 10.13% for the selected period.
- Last close
- $58.84
- Period change
- +10.13%
- Period low
- $52.66
- Period high
- $64.75
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $57.92 | $59.56 | $57.555 | $58.84 | 1.47M |
| Oct 8, 2026 | $59.23 | $59.23 | $56.29 | $57.92 | 2.56M |
| Oct 7, 2026 | $60.85 | $61.375 | $57.33 | $59.72 | 2.91M |
| Oct 6, 2026 | $64.67 | $66.415 | $59.295 | $60.50 | 2.9M |
| Oct 5, 2026 | $63.12 | $64.48 | $62.65 | $63.86 | 2.02M |
| Oct 2, 2026 | $62.25 | $64.36 | $62.25 | $63.24 | 2.23M |
| Oct 1, 2026 | $64.295 | $64.82 | $61.70 | $61.94 | 2.38M |
| Sep 30, 2026 | $64.32 | $66.9808 | $63.86 | $64.75 | 2.14M |
| Sep 29, 2026 | $63.61 | $64.7924 | $62.44 | $64.51 | 1.75M |
| Sep 28, 2026 | $63.22 | $64.95 | $62.37 | $63.28 | 2.61M |
| Sep 25, 2026 | $64.33 | $65.26 | $62.3844 | $64.18 | 2.53M |
| Sep 24, 2026 | $59.17 | $65.00 | $59.17 | $64.00 | 2.26M |
| Sep 23, 2026 | $60.70 | $62.59 | $59.365 | $59.67 | 2.5M |
| Sep 22, 2026 | $62.29 | $62.47 | $60.905 | $61.21 | 1.98M |
| Sep 21, 2026 | $62.05 | $62.67 | $60.57 | $61.58 | 1.6M |
| Sep 18, 2026 | $63.37 | $63.49 | $60.40 | $61.39 | 2.82M |
| Sep 17, 2026 | $61.90 | $64.42 | $61.30 | $63.05 | 3.08M |
| Sep 16, 2026 | $56.64 | $61.72 | $56.61 | $60.67 | 4.11M |
| Sep 15, 2026 | $52.87 | $56.34 | $52.86 | $55.75 | 3.01M |
| Sep 14, 2026 | $53.11 | $53.615 | $51.54 | $52.66 | 2.78M |
| Sep 11, 2026 | $53.77 | $54.33 | $53.08 | $53.43 | 2.09M |
Latest BRKR news
The latest Smart Investors Daily articles mentioning BRKR.
Stock researchCompany · Overview
Company
Market Activity
Research & News
BRKR research
Overview
Company profile and research snapshot.
Company profile
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $49.71
- Implied upside
- —
- Analysts
- 20
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 7, 2026 | Barclays | Overweight | — |
| Oct 1, 2026 | Guggenheim | Buy | — |
| Sep 29, 2026 | Leerink Partners | Outperform | — |
| Sep 9, 2026 | UBS | Neutral | — |
| Aug 5, 2026 | Citigroup | Neutral | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 29, 2026
Leerink Partners Maintains Outperform on Bruker, Raises Price Target to $80
Leerink Partners analyst Puneet Souda maintains Bruker (NASDAQ:BRKR) with a Outperform and raises the price target from $60 to $80.
SeekingAlpha · Sep 22, 2026
Bruker Corporation (BRKR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Bruker Corporation (BRKR) Bank of America Global Healthcare Conference 2026 September 22, 2026 6:45 AM EDTCompany ParticipantsGerald Herman - Executive VP...
Yahoo · Sep 21, 2026
Is Bruker (BRKR) Using Flagship Academic NMR Deals To Deepen Its High-End Moat?
Bruker Corporation previously announced a multi-system order worth more than US$6.00 million from the University of California, Berkeley to equip the Pines Magnetic Resonance Center with next-generation high-field NMR instrumentation, including an AV NEO-X 800 MHz spectrometer with a cryogenically cooled MAS CryoProbe and multiple supporting systems, scheduled for delivery in 2027. This large academic investment highlights how Bruker’s advanced NMR platforms are being embedded in...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
